Loading...
Hyloris Pharmaceuticals SA
HYL.BR•EURONEXT
Healthcare
Biotechnology
€6.90
€0.12(1.77%)
Hyloris Pharmaceuticals SA (HYL.BR) Financial Performance & Income Statement Overview
Review Hyloris Pharmaceuticals SA’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
381.17%
↑ 381.17%
Operating Income Growth
55.42%
↑ 55.42%
Net Income Growth
58.76%
↑ 58.76%
Operating Cash Flow Growth
47.67%
↑ 47.67%
Operating Margin
-71.00%
↓ 71.002%
Gross Margin
97.74%
↑ 97.74%
Net Profit Margin
-63.15%
↓ 63.15%
ROE
-18.99%
↓ 18.99%
ROIC
-20.86%
↓ 20.86%
Hyloris Pharmaceuticals SA (HYL.BR) Income Statement & Financial Overview
Review Hyloris Pharmaceuticals SA's (HYL.BR) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $2.70M | $2.70M | $2.32M | $2.32M |
| Cost of Revenue | $59500.00 | $59500.00 | $54000.00 | $54000.00 |
| Gross Profit | $2.64M | $2.64M | $2.27M | $2.27M |
| Gross Profit Ratio | $0.98 | $0.98 | $0.98 | $0.98 |
| R&D Expenses | $2.48M | $2.48M | $2.66M | $2.66M |
| SG&A Expenses | $1.24M | $1.24M | $1.57M | $1.57M |
| Operating Expenses | $4.22M | $4.22M | $4.25M | $4.25M |
| Total Costs & Expenses | $4.28M | $4.28M | $4.31M | $4.31M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $463500.00 | $463500.00 | $151000.00 | $151000.00 |
| EBITDA | -$609500.00 | -$609500.00 | -$1.81M | -$1.81M |
| EBITDA Ratio | -$0.23 | -$0.23 | -$0.78 | -$0.78 |
| Operating Income | -$1.58M | -$1.58M | -$1.99M | -$1.99M |
| Operating Income Ratio | -$0.58 | -$0.58 | -$0.86 | -$0.86 |
| Other Income/Expenses (Net) | $148500.00 | $148500.00 | $245500.00 | $245500.00 |
| Income Before Tax | -$1.43M | -$1.43M | -$1.74M | -$1.74M |
| Income Before Tax Ratio | -$0.53 | -$0.53 | -$0.75 | -$0.75 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$1.43M | -$1.43M | -$1.74M | -$1.74M |
| Net Income Ratio | -$0.53 | -$0.53 | -$0.75 | -$0.75 |
| EPS | -$0.05 | -$0.05 | -$0.06 | -$0.06 |
| Diluted EPS | -$0.05 | -$0.05 | -$0.06 | -$0.06 |
| Weighted Avg Shares Outstanding | $29.04M | $29.04M | $29.04M | $29.04M |
| Weighted Avg Shares Outstanding (Diluted) | $29.04M | $29.04M | $29.04M | $29.04M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan